Top

Published in:

01-10-2011

Barriers to Use of Pharmacotherapy for Addiction Disorders and How to Overcome Them

Authors: Elizabeth M. Oliva, Natalya C. Maisel, Adam J. Gordon, Alex H. S. Harris

Published in: Current Psychiatry Reports | Issue 5/2011

Abstract

Substance use disorders are highly prevalent, debilitating conditions for which effective pharmacotherapies exist with a broad evidence base, yet pharmacotherapy for the treatment of addiction disorders is underutilized. The goals of this review are to describe the barriers that may contribute to poor adoption and utilization of pharmacotherapy for alcohol and opioid dependence at the system, provider, and patient level and to discuss ways to overcome those barriers. Multifaceted efforts directed at all three levels may be needed to speed pharmacotherapy adoption. More research is needed to help us better understand barriers from patients’ perspectives. Strategies to promote adoption of pharmacotherapy for addiction disorders should be modified to fit the needs of the practice, system, and individual patients. Pharmacotherapy is a valuable tool in the clinical armamentarium of addiction treatment; thus, overcoming barriers to implementation may improve clinical and social outcomes.

Office of Applied Studies: Results from the 2009 National Survey on Drug Use and Health: Detailed Tables. 2009, Substance Abuse and Mental Health Services Administration: Rockville, MD.

Office of National Drug Control Policy: The Economic Costs of Drug Abuse in the United States, 1992–2002. 2004, Executive Office of the President: Washington, DC.

Rehm J, Mathers C, Popova S, et al. Alcohol and global health 1: Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet. 2009;373(9682):2223–33.PubMedCrossRef

Harris AHS, Kivlahan DR, Bowe T, et al. Pharmacotherapy of alcohol use disorders in the Veterans Health Administration. Psychiatr Serv. 2010;61(4):392–8.PubMedCrossRef

Knudsen HK, Abraham AJ, Roman PM. Adoption and implementation of medications in addiction treatment programs. J Addict Med. 2011;5(1):21–7.PubMedCrossRef

Mark TL, Kranzler HR, Poole VH, et al. Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend. 2009;99(1–3):345–9.PubMedCrossRef

Substance Abuse and Mental Health Services Administration: The N-SSATS Report: Services Provided by Substance Abuse Treatment Facilities in the United States. Office of Applied Studies 2009: Rockville, MD.

• Roman PM, Abraham AJ, Knudsen HK. Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation. Addict Behav. 2011;36:584–9. This article describes data obtained from recent US national surveys regarding pharmacotherapy for substance use disorders and discusses facilitators and barriers to pharmacotherapy adoption. PubMedCrossRef

American Psychiatric Association, Physician Consortium for Performance Improvement ® (PCPI), and the National Committee for Quality Assurance: Substance Use Disorders: Physician Performance Measurement Set 2008. Available at http://www.ama-assn.org/ama1/pub/upload/mm/370/sud_ws_final.pdf. Accessed May 2010.

10.

Department of Veterans Affairs and Department of Defense: Management of Substance Use Disorders (SUD). Office of Quality and Performance, VA and Quality Management Office, United States Army MEDCOM 2009: Washington, DC.

11.

Soyka M, Kranzler HR, Berglund M, et al. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of substance use and related disorders, part 1: alcoholism. World J Biol Psychiatry. 2008;9(1):6–23.PubMedCrossRef

12.

Soyka M, Kranzler HR, van den Brink W, et al. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of substance use and related disorders, part 2: opioid dependence. World J Biol Psychiatry. 2011;12:160–87.PubMedCrossRef

13.

Boothby LA, Doering PL. Acamprosate for the treatment of alcohol dependence. Clin Ther. 2005;27(6):695–714.PubMedCrossRef

14.

Snyder JL, Bowers TG. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials. Am J Drug Alcohol Abuse. 2008;34(4):449–61.PubMedCrossRef

15.

Streeton C, Whelan G. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol. 2001;36(6):544–52.PubMed

16.

Bouza C, Angeles M, Munoz A, et al. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction. 2004;99(7):811–28.PubMedCrossRef

17.

Garbutt JC. Efficacy and tolerability of naltrexone in the management of alcohol dependence. Curr Pharm Des. 2010;16(19):2091–7.PubMedCrossRef

18.

Rösner S, Hackl-Herrwerth A, Leucht S, et al. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010, Issue 12. Art. No.: CD001867.

19.

Kranzler HR, Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta analysis. Alcohol Clin Exp Res. 2001;25(9):1335–41.PubMedCrossRef

20.

Rösner S, Leucht S, Lehert P, et al. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol. 2008;22(1):11–23.PubMedCrossRef

21.

Rösner S, Hackl-Herrwerth A, Leucht S, et al. Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2010, Issue 9. Art. No.: CD004332.

22.

Mattick R, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009, Issue 3. Art. No.: CD002209.

23.

Mattick R, Kimber J, Breen C, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008, Issue 2. Art. No.: CD002207.

24.

Mattick RP, Ali R, White JM, et al. Buprenorphine versus methadone maintenance therapy: a randomized double blind trial with 405 opioid dependent patients. Addiction. 2003;98(4):441–52.PubMedCrossRef

25.

Barnett PG. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction. 2009;104(6):982–92.PubMedCrossRef

26.

Barnett PG, Zaric GS, Brandeau ML. The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction. 2001;96(9):1267–78.PubMedCrossRef

27.

Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007, 11(9):iii–171.

28.

Fiellin DA, Rosenheck RA, Kosten TR. Office-based treatment for opioid dependence: reaching new patient populations. Am J Psychiatry. 2001;158(8):1200–4.PubMedCrossRef

29.

Sullivan LE, Fiellin DA. Narrative review: buprenorphine for opioid-dependent patients in office practice. Ann Intern Med. 2008;148(9):662–70.PubMed

30.

Becker WC, Fiellin DA, Merrill JO, et al. Opioid use disorder in the United States: insurance status and treatment access. Drug Alcohol Depend. 2008;94(1–3):207–13.PubMedCrossRef

31.

Ducharme LJ, Abraham AJ. State policy influence on the early diffusion of buprenorphine in community treatment programs. Subst Abuse Treat Prev Policy. 2008;3(1):17.PubMedCrossRef

32.

Finkelstein R, Netherland J, Sylla L, et al. Policy implications of integrating buprenorphine/naloxone treatment and HIV care. J Acquir Immune Defic Syndr. 2011;56:S98–S104.PubMedCrossRef

33.

Knudsen HK, Roman PM, Oser CB. Facilitating factors and barriers to the use of medications in publicly funded addiction treatment organizations. J Addict Med. 2010;4(2):99–107.PubMedCrossRef

34.

Lobmaier P, Gossop M, Waal H, et al. The pharmacological treatment of opioid addiction—a clinical perspective. Eur J Clin Pharmacol. 2010;66(6):537–45.PubMedCrossRef

35.

Mark TL, Kassed CA, Vandivort-Warren R, et al. Barriers to the use of medications to treat alcoholism. Am J Addict. 2003;12(4):281–94.PubMed

36.

Rieckmann T, Kovas AE, Rutkowski BA. Adoption of medications in substance abuse treatment: priorities and strategies of single state authorities. J Psychoactive Drugs. 2010;Supplement 6:227–38.

37.

Thomas CP, Wallack SS, Lee S, et al. Research to practice: adoption of naltrexone in alcoholism treatment. J Subst Abuse Treat. 2003;24(1):1–11.PubMedCrossRef

38.

• Weber EM. Failure of physicians to prescribe pharmacotherapies for addiction: regulatory restrictions and physician resistance. J Health Care Law Policy 2010;13:49–76. This article provides a good historical overview of factors contributing to low utilization of pharmacotherapies for addiction.

39.

Horgan CM, Reif S, Hodgkin D, et al. Availability of addiction medications in private health plans. J Subst Abuse Treat. 2008;34(2):147–56.PubMedCrossRef

40.

Knudsen HK, Abraham AJ, Johnson JA, et al. Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat. 2009;37(3):307–12.PubMedCrossRef

41.

Knudsen HK, Ducharme LJ, Roman PM. The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters. Drug Alcohol Depend. 2007;87(2–3):164–74.PubMedCrossRef

42.

Stöver H. Barriers to opioid substitution treatment access, entry and retention: a survey of opioid users, patients in treatment, and treating and non-treating physicians. Eur Addict Res. 2011;17(1):44–54.PubMedCrossRef

43.

Walley AY, Alperen JK, Cheng DM, et al. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med. 2008;23(9):1393–8.PubMedCrossRef

44.

Netherland J, Botsko M, Egan JE, et al. Factors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat. 2009;36(3):244–51.PubMedCrossRef

45.

Heinrich CJ, Hill CJ. Role of state policies in the adoption of naltrexone for substance abuse treatment. Health Serv Res. 2008;43(3):951–70.PubMedCrossRef

46.

Albright J, Ciaverelli R, Essex A, et al. Psychiatrist characteristics that influence use of buprenorphine medication-assisted treatment. J Addict Med. 2010;4(4):197–203.PubMedCrossRef

47.

Humphreys K, Trafton JA, Oliva EM. Does following research-derived practice guidelines improve opiate-dependent patients’ outcomes under everyday practice conditions?: results of the multisite opiate substitution treatment study. J Subst Abuse Treat. 2008;34(2):173–9.PubMedCrossRef

48.

Abraham AJ, Ducharme LJ, Roman PM. Counselor attitudes toward pharmacotherapies for alcohol dependence. J Stud Alcohol Drugs. 2009;70(4):628–35.PubMed

49.

Bacha J, Reast S, Pearlstone A. Treatment practices and perceived challenges for European physicians treating opioid dependence. Heroin Addict Relat Clin Probl. 2010;12(3):9–19.

50.

Barry DT, Irwin KS, Jones ES, et al. Integrating buprenorphine treatment into office-based practice: a qualitative study. J Gen Intern Med. 2009;24(2):218–25.PubMedCrossRef

51.

Drake R, Skinner J, Goldman HH. What explains the diffusion of treatments for mental illness? Am J Psychiatry. 2008;165(11):1385–92.PubMedCrossRef

52.

Wallack SS, Thomas CP, Martin TC, et al. Substance abuse treatment organizations as mediators of social policy: slowing the adoption of a Congressionally approved medication. J Behav Health Serv Res. 2010;37(1):64–78.PubMedCrossRef

53.

Gordon A, Kavanagh G, Krumm M, et al. Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration. Psychol Addict Behav. 2011;25(2):215–24.

54.

Fitzgerald J, McCarty D. Understanding attitudes toward use of medication in substance abuse treatment: a multilevel approach. Psychol Serv. 2009;6(1):74–84.PubMedCrossRef

55.

Lundgren L, Krull I, Zerden LS, et al. Community based addiction treatment staff attitudes about the usefulness of evidence-based addiction treatment and CBO organizational linkages to research institutions. Eval Program Plann. 2011;34(4):356–65.

56.

Dackis C, O’Brien C. Neurobiology of addiction: treatment and public policy ramifications. Nat Neurosci. 2005;8(11):1431–6.PubMedCrossRef

57.

Littleton JM, de Witte P, Litten R, et al. Challenges to medications development in treating alcohol dependence: an international perspective. Alcohol Alcohol. 2004;39(4):271–5.PubMed

58.

Center for Substance Abuse Treatment: Incorporating Alcohol Pharmacotherapies Into Medical Practice. Treatment Improvement Protocol (TIP) Series 49. Substance Abuse and Mental Health Services Administration 2009: Rockville, MD.

59.

McAuley K, Maurice D, Ferguson A, et al. Evaluation of the impact of medication assisted treatment in Maine. Department of Health and Human Services, Maine Office of Substance Abuse. South Portland: Hornby Zeller Associates, Inc.; 2010.

60.

McCarty D, Perrin NA, Green CA, et al. Methadone maintenance and the cost and utilization of health care among individuals dependent on opioids in a commercial health plan. Drug Alcohol Depend. 2010;111(3):235–40.PubMedCrossRef

61.

Fornili K, Burda C. Buprenorphine prescribing: why physicians aren’t and nurse prescribers can’t. J Addict Nurs. 2009;20(4):218–26.CrossRef

62.

Cunningham CO, Sohler NL, McCoy K, et al. Attending physicians’ and residents’ attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital. Fam Med. 2006;38(5):336–40.PubMed

63.

Thomas SE, Miller PM. Knowledge and attitudes about pharmacotherapy for alcoholism: a survey of counselors and administrators in community-based addiction treatment centres. Alcohol Alcohol. 2007;42(2):113–8.PubMed

64.

O’Connor PG, Nyquist JG, McLellan AT. Integrating addiction medicine into graduate medical education in primary care: the time has come. Ann Intern Med. 2011;154(1):56–9.PubMed

65.

Martino S, Brigham GS, Higgins C, et al. Partnerships and pathways of dissemination: The National Institute on Drug Abuse--Substance Abuse and Mental Health Services Administration Blending Initiative in the Clinical Trials Network. J Subst Abuse Treat. 2010;38(Supplement 1):S31–43.PubMedCrossRef

66.

Gordon AJ, Liberto J, Granda S, et al. Outcomes of DATA 2000 certification trainings for the provision of buprenorphine treatment in the Veterans Health Administration. Am J Addict. 2008;17(6):459–62.PubMedCrossRef

67.

Gordon AJ, Liberto J, Granda S, et al. Physician training is never a failure. Am J Addict. 2009;18(4):337–8.CrossRef

68.

Anton RF, O’Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003–17.PubMedCrossRef

69.

West JC, Kosten TR, Wilk J, et al. Challenges in increasing access to buprenorphine treatment for opiate addiction. Am J Addict. 2004;13(S1):S8–S16.PubMedCrossRef

70.

Ridge G, Gossop M, Lintzeris N, et al. Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. J Subst Abuse Treat. 2009;37(1):95–100.PubMedCrossRef

71.

Cunningham CO, Kunins HV, Roose RJ, et al. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. J Gen Intern Med. 2007;22(9):1325–9.PubMedCrossRef

72.

Turner BJ, Laine C, Lin Y, et al. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence. Arch Intern Med. 2005;165(15):1769–76.PubMedCrossRef

73.

Strobbe S, Mathias L, Gibbons PW, et al. Buprenorphine clinic for opioid maintenance therapy: program description, process measures, and patient satisfaction. J Addict Nurs. 2011;22:8–12.CrossRef

74.

Egan JE, Casadonte P, Gartenmann T, et al. The physician clinical support system-buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment. J Gen Intern Med. 2010;25(9):936–41.PubMedCrossRef

75.

Abraham AJ, Rieckmann T, McNulty T, et al. Counselor attitudes toward the use of naltrexone in substance abuse treatment: a multi-level modeling approach. Addict Behav. 2011;36(6):576–83.PubMedCrossRef

76.

Kahan M, Srivastava A, Ordean A, et al. Buprenorphine: new treatment of opioid addiction in primary care. Can Fam Physician. 2011;57(3):281–9.PubMed

Title: Barriers to Use of Pharmacotherapy for Addiction Disorders and How to Overcome Them
Authors: Elizabeth M. Oliva
Natalya C. Maisel
Adam J. Gordon
Alex H. S. Harris
Publication date: 01-10-2011
Publisher: Current Science Inc.
Published in: Current Psychiatry Reports / Issue 5/2011
Print ISSN: 1523-3812
Electronic ISSN: 1535-1645
DOI: https://doi.org/10.1007/s11920-011-0222-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Barriers to Use of Pharmacotherapy for Addiction Disorders and How to Overcome Them

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2011

Adult Attention-Deficit/Hyperactivity Disorder and Driving: Why and How to Manage It

Clonidine Extended Release in the Treatment of Attention-Deficit/Hyperactivity Disorder

Potential Roles for New Communication Technologies in Treatment of Addiction

Updates on Attention-Deficit/Hyperactivity Disorder and Learning Disorders

Recent Advances in Behavioral Addiction Treatments: Focusing on Mechanisms of Change

Dietary and Nutritional Treatments for Attention-Deficit/Hyperactivity Disorder: Current Research Support and Recommendations for Practitioners